Catherine A Morelli, PA-C
Guthrie Provider
- Hematology
- Medical Oncology
- Guthrie Robert Packer Hospital
Clinical Interests
- Leukemia
- Lymphoma
- Neuro-oncology
- Pediatric oncology
- Sickle Cell Anemia
Locations
Education
- Quinnipiac University, Hamden, Conn. (Physician Assistant)
Clinical Trials
- A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T
- A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
- A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
- A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
- A171901: OLDER NON-SMALL CELL LUNG CANCER PATIENTS (>/= 70 YEARS OF AGE) TREATED WITH FIRST-LINE MK-3475 (PEMBROLIZUMAB) +/- CHEMOTHERAPY (ONCOLOGIST'S/PATIENT'S CHOICE)
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- AFT-25 COMET Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
- ARC-7, Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- BNT111-01: Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
- E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
- EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.
- EA6134:DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing); A Phase III Trial
- EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
- ICP-CL-00107: A Phase I/II Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies
- Isolation of Oxaliplatin-Resistant Circulating Tumor Cells from Colorectal Cancer Patient Blood
- LungMap (Screening Protocol for Lung-Map):
- MATCH EAY131, Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
- NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
- NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
- NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
- NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
- S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
- S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Patient Comments